TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
IQV

IQVIA Holdings Inc

Healthcare · Diagnostics & Research

238.70$ +2.7% vs. previous close Closing price · As of: Aug 7, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of IQVIA Holdings Inc (IQV). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — IQV
Segment 2020 2021 2022 2023 2024 2025
Research & Development Solutions $5.76B 50.7% $7.56B 54.5% · +31.2% $7.92B 55.0% · +4.8% $8.40B 56.0% · +6.0% $8.53B 55.4% · +1.6% $8.90B 54.5% · +4.3%
Technology & Analytics Solutions $4.86B 42.8% $5.53B 39.9% · +13.9% $5.75B 39.9% · +3.8% $5.86B 39.1% · +2.0% $6.16B 40.0% · +5.1% $6.63B 40.6% · +7.6%
Contract Sales & Medical Solutions $741.0M 6.5% $784.0M 5.7% · +5.8% $743.0M 5.2% · -5.2% $727.0M 4.9% · -2.2% $718.0M 4.7% · -1.2% $788.0M 4.8% · +9.7%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by region

Revenue by region — IQV
Segment 2020 2021 2022 2023 2024 2025
Americas $5.42B 47.7% $6.85B 49.4% · +26.4% $7.05B 48.9% · +2.9% $7.55B 50.4% · +7.2% $7.36B 47.8% · -2.6% $7.75B 47.5% · +5.3%
Europe and Africa $3.70B 32.5% $4.36B 31.4% · +17.9% $4.37B 30.3% · +0.2% $4.46B 29.8% · +2.1% $4.92B 31.9% · +10.3% $5.19B 31.8% · +5.4%
Asia-Pacific $2.25B 19.8% $2.67B 19.2% · +18.9% $3.00B 20.8% · +12.3% $2.97B 19.8% · -0.8% $3.13B 20.3% · +5.2% $3.38B 20.7% · +8.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?